Voss Capital's Sale Push: What the Smart Money Is Really Saying

The letter landed last week. Hedge fund Voss Capital formally urged Xponential Fitness to explore a sale to private investors. On the surface, it sounds like a call for a strategic move. But for the smart money, this is a classic signal. It's a whale wallet raising a red flag, not a buy recommendation.

The thesis is simple: Voss's urging is a trap for retail investors, not a genuine value opportunity. The fund's own skin in the game tells the real story. Its 13F filing shows a 2.2% stake in the company. That's a focused, tactical position, not a long-term belief in a turnaround. Whales like Voss don't push for sales unless they see a distressed asset with a weak growth story they can exit before the music stops.

The market's skepticism is already baked into the price. The stock is down 47% over the past year, trading at a 24% discount to its 52-week low. This isn't a healthy discount; it's a deep-value trap. When the smart money sees a company priced this poorly, their instinct is often to sell, not to buy. Voss's letter is the institutional version of a warning label: "This asset is broken, and the story isn't getting better."

The bottom line is alignment of interest. Voss has no incentive to pump the stock for retail investors. Its goal is to maximize returns on its own position, and the clearest path right now is a sale that lets it cut its losses. For everyone else, the urging is a signal to look away.

The Financial Reality: A Growth Model in Reset

The smart money isn't just reacting to a sales letter; it's seeing a broken growth model. The headline numbers are a distraction. The real story is in the underlying performance, where franchisee demand is clearly weakening.

Take system-wide sales. They grew 5% last quarter, which sounds positive. But that figure includes new studio openings, masking a deeper problem. The metric that matters for franchisee skin in the game is same-store sales. In North America, those fell 4.3% for the quarter. That's a sharp reversal from the 7% growth seen a year ago. It means existing locations are losing revenue, a clear sign that the core business is under pressure. The company's own data shows this is a portfolio-wide issue, with brands like StretchLab seeing negative 12% full-year same-store sales.

This deterioration is hitting profitability hard. Adjusted EBITDA plunged 26% last quarter, and the company posted a $45.6 million net loss. That's a dramatic drop from the prior year. The smart money sees this as a warning: the model that once drove expansion is now burning cash. The guidance for 2026 confirms the reset. Management's revenue forecast implies a double-digit percentage decline from 2025. This isn't just a slowdown; it's a formal abandonment of prior growth narratives. The company is pausing aggressive studio openings to focus on fixing the existing business and cleaning up its balance sheet.

The bottom line is a profitability crisis. When same-store sales fall and EBITDA collapses, it erodes the very foundation of a franchise model. The smart money is looking at these numbers and seeing a company in a reset, not a turnaround. The urging for a sale is a call to exit before the financial reality fully sets in.

Insider Alignment: Skin in the Game or Skin in the Exit?

The smart money doesn't just read letters; it watches wallets. For Xponential Fitness, the ultimate signal of alignment-or lack thereof-comes from the company's own executives and major shareholders. Their actions with their own money tell a story that headlines often obscure.

The record shows a pattern of selling. The CFO, John Meloun, made a notable purchase of 536,690 shares in August 2025, but that was his only reported transaction in the last year. More telling is the broader trend of stock awards granted at $0.00 per share to directors and officers, including the CEO and CFO, in late 2025. This isn't a sign of skin in the game; it's a mechanism for compensation that dilutes existing shareholders. When insiders are paid in free shares while the stock trades near multi-year lows, it signals a disconnect from the public price.

The board's response to Voss Capital's urging will be the next key test. The hedge fund's letter, which called for a sale, is a direct challenge to the board's stewardship. If the board moves to hire an independent advisor to explore a sale, it could be seen as a responsible step. But for the smart money, the real question is whether the board itself is aligned with a public sale or if it's also looking to exit. The board's composition, with several directors holding significant stakes, will be scrutinized for any hidden exits.

The company's recent capital restructuring adds another layer of complexity. The planned $525 million term loan and a proposed $17 million FTC settlement are steps to strengthen the balance sheet. But they also create a scenario where a clean sale to private equity becomes a plausible, if not ideal, outcome. Private equity firms are often the buyers in these situations, providing the capital to fix operations and clean up regulatory overhangs. The board's path forward will reveal whether they see a private sale as the best exit for all parties-or if they're hoping for a public market recovery that insiders may not be betting on.

The bottom line is a lack of visible skin in the game. With executives selling and insiders being paid in free shares, the alignment of interest is weak. Voss Capital's letter is a warning label, but the insiders' wallets are the final verdict. When the smart money sees a board and executives with little at risk, their instinct is to look for an exit.

Catalysts and Risks: What to Watch for the Thesis

The smart money's pessimistic view hinges on a few key catalysts and hurdles. The next few months will test whether the warning signs are being validated or dismissed.

First, watch for the board's formal response to Voss Capital's letter. The hedge fund's urging is a direct challenge to the board's stewardship. Silence or resistance would signal a lack of alignment with the fund's view, suggesting the board may be hoping for a public market recovery that insiders aren't betting on. A move to hire an independent advisor to explore a sale, however, would be a major validation of the smart money's thesis. This is the first major test of whether the board sees a distressed asset or a turnaround story.

The next earnings report is the critical data point. Any further deterioration in same-store sales or a fresh round of guidance cuts would confirm the reset is accelerating. Management's own 2026 revenue forecast implies a double-digit percentage decline from 2025. If the company misses that mark, it would prove the growth model is broken beyond repair. The market's reaction to that report will be the ultimate validation-or contradiction-of the sale thesis.

Finally, monitor the execution of two major operational and financial hurdles. The proposed $17 million FTC settlement must be approved by the FTC. This is a regulatory hurdle that, if cleared, would resolve a significant overhang. At the same time, the new $525 million term loan must close. This capital is essential for the company's balance sheet and its 2026 plan to invest in performance marketing and studio upgrades. The successful closing of this loan would be a positive step, but it also creates a scenario where a clean sale to private equity becomes a more plausible exit. The board's path forward will reveal whether they see a private sale as the best outcome-or if they're hoping for a public market recovery that insiders may not be betting on.

The watch list is clear. The board's response, the next earnings print, and the resolution of these two key hurdles will determine if the smart money's trap is closing in.